ECSP066992A - ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB - Google Patents

ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB

Info

Publication number
ECSP066992A
ECSP066992A EC2006006992A ECSP066992A ECSP066992A EC SP066992 A ECSP066992 A EC SP066992A EC 2006006992 A EC2006006992 A EC 2006006992A EC SP066992 A ECSP066992 A EC SP066992A EC SP066992 A ECSP066992 A EC SP066992A
Authority
EC
Ecuador
Prior art keywords
inhibitor
phenylpiridin
methylaminopirimidin
ilamino
indol
Prior art date
Application number
EC2006006992A
Other languages
English (en)
Inventor
Olaf Ritzeler
El-Bdaoui Haddad
David John Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP066992A publication Critical patent/ECSP066992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención está dirigida al compuesto sustancialmente puro de fórmula (A), (A)o una sal farmacéuticamente aceptable, o solvato de dicho compuesto; a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula (A), y un vehículo farmacéuticamente aceptable; y al uso de un compuesto de fórmula (A) que tiene actividad como inhibidor, preferiblemente un inhibidor selectivo, de IkB (IKK), en particular IKK-2, y a métodos relacionados con ello.
EC2006006992A 2004-05-12 2006-11-10 ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB ECSP066992A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
ECSP066992A true ECSP066992A (es) 2006-12-29

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006992A ECSP066992A (es) 2004-05-12 2006-11-10 ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB

Country Status (23)

Country Link
EP (1) EP1747215A1 (es)
JP (1) JP2007537266A (es)
KR (1) KR20070011483A (es)
CN (1) CN1950359A (es)
AR (1) AR049274A1 (es)
AU (1) AU2005245834A1 (es)
BR (1) BRPI0511029A (es)
CA (1) CA2566213A1 (es)
EC (1) ECSP066992A (es)
GT (1) GT200500111A (es)
IL (1) IL178992A0 (es)
MA (1) MA28553B1 (es)
MX (1) MXPA06012870A (es)
NO (1) NO20065719L (es)
PA (1) PA8633101A1 (es)
PE (1) PE20060269A1 (es)
RU (1) RU2006143758A (es)
SV (1) SV2006002111A (es)
TN (1) TNSN06338A1 (es)
TW (1) TW200605881A (es)
UY (1) UY28897A1 (es)
WO (1) WO2005113544A1 (es)
ZA (1) ZA200608712B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5634596B2 (ja) * 2010-04-27 2014-12-03 ハチソン メディファーマ リミテッド ピリミジニルインドール化合物
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
PE20060269A1 (es) 2006-05-11
SV2006002111A (es) 2006-01-30
ZA200608712B (en) 2008-06-25
NO20065719L (no) 2006-12-12
PA8633101A1 (es) 2006-01-23
CA2566213A1 (en) 2005-12-11
GT200500111A (es) 2006-05-09
MXPA06012870A (es) 2007-02-15
TNSN06338A1 (en) 2008-02-22
EP1747215A1 (en) 2007-01-31
AR049274A1 (es) 2006-07-12
IL178992A0 (en) 2007-03-08
AU2005245834A1 (en) 2005-12-01
MA28553B1 (fr) 2007-04-03
TW200605881A (en) 2006-02-16
RU2006143758A (ru) 2008-06-27
BRPI0511029A (pt) 2007-11-27
JP2007537266A (ja) 2007-12-20
KR20070011483A (ko) 2007-01-24
UY28897A1 (es) 2005-12-30
CN1950359A (zh) 2007-04-18
WO2005113544A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
ECSP066992A (es) ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
ECSP088258A (es) Inhibidores de serina proteasas
UY32062A (es) Inhibidores de beta-secretasa
EA200900676A1 (ru) Ингибиторы вируса гепатита с
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
AR056764A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
BRPI0507972A (pt) composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
UY29007A1 (es) Derivados de 2-carbamida-4-feniltiazol, su preparacinn, y su aplicacinn en terapcutica
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR061134A1 (es) Derivados de tioxantina
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica